Summarized by Masters of Longevity from Longevity Technology.
Diabetic retinopathy gene therapy update — a three-year interim look at clinical progress and what readers should expect from the full article.
Key Takeaways
- Six of ten patients showed two-or-more step improvement on a diabetic retinopathy severity scale at three years.
- Results are interim self-analyses from a small Phase II ALTITUDE trial and include at least one patient lost to follow-up.
- Dose Level 3 is being advanced into the larger Phase IIb/III NAAVIGATE trial in non-proliferative diabetic retinopathy.
